Kai Yeung1,2, Weiwei Zhu1, Susan M McCurry3, Michael Von Korff1, Robert Wellman1, Charles M Morin4, Michael V Vitiello5. 1. Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA. 2. University of Washington, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Seattle, Washington, USA. 3. Department of Child, Family, and Population Health Nursing, University of Washington School of Nursing, Seattle, Washington, USA. 4. Department of Psychology, Université Laval, Quebec City, Quebec, Canada. 5. Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA.
Abstract
BACKGROUND: Osteoarthritis-related insomnia is the most common form of comorbid insomnia among older Americans. A randomized clinical trial found that six sessions of telephone-delivered cognitive behavioral therapy for insomnia (CBT-I) improved sleep outcomes in this population. Using these data, we evaluated the incremental cost-effectiveness of CBT-I from a healthcare sector perspective. METHODS: The study was based on 325 community-dwelling older adults with insomnia and osteoarthritis pain enrolled with Kaiser Permanente of Washington State. We measured quality-adjusted life years (QALYs) using the EuroQol 5-dimension scale. Arthritis-specific quality of life was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Insomnia-specific quality of life was measured using the Insomnia Severity Index (ISI) and nights without clinical insomnia (i.e., "insomnia-free nights"). Total healthcare costs included intervention and healthcare utilization costs. RESULTS: Over the 12 months after randomization, CBT-I improved ISI and WOMAC by -2.6 points (95% CI: -2.9 to -2.4) and -2.6 points (95% CI: -3.4 to -1.8), respectively. The ISI improvement translated into 89 additional insomnia-free nights (95% CI: 79 to 98) over the 12 months. CBT-I did not significantly reduce total healthcare costs (-$1072 [95% CI: -$1968 to $92]). Improvements in condition-specific measures were not reflected in QALYs gained (-0.01 [95% CI: -0.01 to 0.01]); at a willingness-to-pay of $150,000 per QALY, CBT-I resulted in a positive net monetary benefit of $369 with substantial uncertainty (95% CI: -$1737 to $2270). CONCLUSION: CBT-I improved sleep and arthritis function without increasing costs. These findings support the consideration of telephone CBT-I for treating insomnia among older adults with comorbid OA. Our findings also suggest potential limitations of the general quality of life measures in assessing interventions designed to improve sleep and arthritis outcomes.
BACKGROUND: Osteoarthritis-related insomnia is the most common form of comorbid insomnia among older Americans. A randomized clinical trial found that six sessions of telephone-delivered cognitive behavioral therapy for insomnia (CBT-I) improved sleep outcomes in this population. Using these data, we evaluated the incremental cost-effectiveness of CBT-I from a healthcare sector perspective. METHODS: The study was based on 325 community-dwelling older adults with insomnia and osteoarthritis pain enrolled with Kaiser Permanente of Washington State. We measured quality-adjusted life years (QALYs) using the EuroQol 5-dimension scale. Arthritis-specific quality of life was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Insomnia-specific quality of life was measured using the Insomnia Severity Index (ISI) and nights without clinical insomnia (i.e., "insomnia-free nights"). Total healthcare costs included intervention and healthcare utilization costs. RESULTS: Over the 12 months after randomization, CBT-I improved ISI and WOMAC by -2.6 points (95% CI: -2.9 to -2.4) and -2.6 points (95% CI: -3.4 to -1.8), respectively. The ISI improvement translated into 89 additional insomnia-free nights (95% CI: 79 to 98) over the 12 months. CBT-I did not significantly reduce total healthcare costs (-$1072 [95% CI: -$1968 to $92]). Improvements in condition-specific measures were not reflected in QALYs gained (-0.01 [95% CI: -0.01 to 0.01]); at a willingness-to-pay of $150,000 per QALY, CBT-I resulted in a positive net monetary benefit of $369 with substantial uncertainty (95% CI: -$1737 to $2270). CONCLUSION: CBT-I improved sleep and arthritis function without increasing costs. These findings support the consideration of telephone CBT-I for treating insomnia among older adults with comorbid OA. Our findings also suggest potential limitations of the general quality of life measures in assessing interventions designed to improve sleep and arthritis outcomes.
Authors: A Simon Pickard; Ernest H Law; Ruixuan Jiang; Eleanor Pullenayegum; James W Shaw; Feng Xie; Mark Oppe; Kristina S Boye; Richard H Chapman; Cynthia L Gong; Alan Balch; Jan J V Busschbach Journal: Value Health Date: 2019-05-25 Impact factor: 5.725
Authors: Andrea N Natsky; Andrew Vakulin; Ching L Chai-Coetzer; Leon Lack; R D McEvoy; Nicole Lovato; Alexander Sweetman; Christopher J Gordon; Robert J Adams; Billingsley Kaambwa Journal: Sleep Med Rev Date: 2020-07-09 Impact factor: 11.609
Authors: Maureen C O'Keeffe-Rosetti; Mark C Hornbrook; Paul A Fishman; Debra P Ritzwoller; Erin M Keast; Jenny Staab; Jennifer Elston Lafata; Ramzi Salloum Journal: J Natl Cancer Inst Monogr Date: 2013
Authors: Kannan Ramar; Raman K Malhotra; Kelly A Carden; Jennifer L Martin; Fariha Abbasi-Feinberg; R Nisha Aurora; Vishesh K Kapur; Eric J Olson; Carol L Rosen; James A Rowley; Anita V Shelgikar; Lynn Marie Trotti Journal: J Clin Sleep Med Date: 2021-10-01 Impact factor: 4.324